» Articles » PMID: 26015275

Recent Advances in Traditional Chinese Medicine for Kidney Disease

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2015 May 28
PMID 26015275
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Because current treatment options for chronic kidney disease (CKD) are limited, many patients seek out alternative therapies such as traditional Chinese medicine. However, there is a lack of evidence from large clinical trials to support the use of traditional medicines in patients with CKD. Many active components of traditional medicine formulas are undetermined and their toxicities are unknown. Therefore, there is a need for research to identify active compounds from traditional medicines and understand the mechanisms of action of these compounds, as well as their potential toxicity, and subsequently perform well-designed, randomized, controlled, clinical trials to study the efficacy and safety of their use in patients with CKD. Significant progress has been made in this field within the last several years. Many active compounds have been identified by applying sophisticated techniques such as mass spectrometry, and more mechanistic studies of these compounds have been performed using both in vitro and in vivo models. In addition, several well-designed, large, randomized, clinical trials have recently been published. We summarize these recent advances in the field of traditional medicines as they apply to CKD. In addition, current barriers for further research are also discussed. Due to the ongoing research in this field, we believe that stronger evidence to support the use of traditional medicines for CKD will emerge in the near future.

Citing Articles

Therapeutic potential of -based Eefooton in patients with chronic kidney disease: from clinical to bench study.

Lu K, Kuo K, Wu S, Lin C, Lin C, Hou Y Int J Med Sci. 2025; 22(1):227-239.

PMID: 39744164 PMC: 11659832. DOI: 10.7150/ijms.102280.


Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease.

Elenjickal E, Valson A, Varughese S, Vincent L, Fernando E, Natarajan G Front Pharmacol. 2024; 15:1531748.

PMID: 39726783 PMC: 11670803. DOI: 10.3389/fphar.2024.1531748.


Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3-4: a retrospective cohort study.

Chu A, Wei W, Liu N, Zhang F, Zhang X, Li X Front Med (Lausanne). 2024; 11:1450561.

PMID: 39380733 PMC: 11458470. DOI: 10.3389/fmed.2024.1450561.


Therapeutic Effect of Desmodium caudatum Extracts on Alleviating Diabetic Nephropathy Mice.

Lin H, Tseng C, Yu P, Ho H, Hsu C, Chen J Plant Foods Hum Nutr. 2024; 79(2):374-380.

PMID: 38750193 DOI: 10.1007/s11130-024-01192-9.


N1F(Improved-Nephropathy 1 Formula) Ameliorates Renal Interstitial Fibrosis via Inhibiting Extracellular Matrix Deposition and Regulating the FGF23/P38MAPK/Wnt Pathway.

Yu W, Zeng C, Wang C, Jia S, Liu C, Zeng Y Cell Biochem Biophys. 2024; 82(2):927-943.

PMID: 38722471 DOI: 10.1007/s12013-024-01244-6.